Paul Brown

Vice President, Drug Product Innovation

Paul Brown, Ph.D. leads the company’s Innovation team. In this role, he’s accountable for evolving and optimizing the company’s current technology platform and potential uses, while also exploring new methodologies and opportunities of impact. He is a physical chemist and one of the scientific co-founders of Elektrofi’s proprietary formulation technology platform. Paul plays a vital role in the company’s growth across drug product development, process scale-up, translation, and device selection.

Prior to joining Elektrofi, Paul worked at several research institutions, including the Massachusetts Institute of Technology, Oakridge National Laboratory, and the Rutherford Appleton Laboratory, where he authored 45 peer-reviewed papers in the fields of biology, materials science, chemical engineering, and physics. His proven expertise in interface and colloid science and its applications across pharmaceuticals, biotechnology, nanotechnology, and materials led to his developing 18 registered patents.

Paul holds a Ph.D. in Physical Chemistry and a Master in Chemistry from the University of Bristol. 

Vice President, Head of Program Management and Strategy

Lyndon Charles is Vice President and Head of Program Management and Strategy, responsible for driving Elektrofi’s partnership programs and pipeline, and ensuring program goals are being met collaboratively, with efficiency, quality, and speed. He leverages his broad range of experience to enable a holistic view of our programs to prioritize activities, proactively manage challenges and find synergies, and actively pursue shared goals for developing and commercializing assets. 

Lyndon is a biomedical engineer and scientist who is passionate about leading diverse teams to develop new technologies in the pursuit of solving complex biomedical problems. 

Prior to joining Elektrofi, he served as a postdoctoral Research Scientist at the Massachusetts Institute of Technology, a Research Assistant at the University of Connecticut, and a National Science Foundation Research Scholar awardee at École Polytechnique Fédérale de Lausanne (EPFL).  Across these roles, Lyndon managed cross functional teams and worked on highly collaborative academia-industry partnerships with companies such as Sanofi, BioTime, and Aruna BIO. Lyndon has authored 11 peer reviewed papers in the fields of drug delivery, regenerative engineering, and aging. His proven expertise in the development of novel drug delivery technologies and their applications across regenerative medicine has led to intellectual property supporting the commercialization of products and launching of biotech startups. 

Lyndon holds Ph.D. in Biomedical Science, and a Bachelor of Science in Biomedical Engineering from the University of Connecticut. 

Vice President, Head of Science

Daniel B. Dadon is a Vice President and Head of Science responsible multiple technical, corporate, and business functions, including governing the company’s translational, formulation, and analytical R&D priorities. He is a biologist and one of the scientific co-founders of Elektrofi.

Prior to joining Elektrofi, Daniel served as the Scientific Strategy and Corporate Development Fellow at Evelo Biosciences, a Flagship Pioneering company, working on microbiome therapeutics. As a National Science Foundation (NSF) Fellow at the Whitehead Institute of Massachusetts Institute of Technology (MIT), Daniel studied the underlying principles of the transcriptional control of cell identity. While at MIT he contributed to science through seminal publications and licensed patents in the spaces of 3D genomics/epigenomics, genome engineering (CRISPR, TALEN), artificial transcription factor technology, and chromatin proteomic mass spectrometry. Prior, Daniel was in the HHMI McCammon Laboratory at UC San Diego performing computational biophysics to conduct molecular dynamic and docking simulations to identify small molecule inhibitors of swine (H1N1) flu. He also worked at Biogen Idec in the Process Development group optimizing the chromatographic purification of Tysabri®. Before Biogen Idec, he started his scientific career investigating various gene therapy approaches at the Center for Neural Repair lab at the UC San Diego Medical School. 

Daniel holds a Ph.D. in Biology from MIT and a Bachelor of Science in Molecular Biology from UC San Diego. He’s completed coursework at the Massachusetts Institute of Technology Sloan School of Management and has made scientific contributions through groundbreaking publications and licensed patents.

Vice President, Pharmaceutical Development

Willow DiLuzio leads the company’s Pharmaceutical Development Team responsible for formulation development and process development for clinical development programs and for progressing Elektrofi’s formulation and process platform technology and understanding. 

Willow has over 20 years of experience in protein and small molecule formulation development, drug product process development, aseptic drug product manufacturing, combination product development and manufacturing, definition of analytical and process control strategies, CMC program management, CMC regulatory strategy and CMC organizational design.  Prior to joining Elektrofi, Willow was Vice President of Pharmaceutical Development and CMC Program Management at Sarepta where she was a key contributor to the development and regulatory approval of oligonucleotide and gene therapy products including Vyondys 53®, Amondys 45®, and Elevidys®.

Prior to Sarepta, Willow worked at Millennium/Takeda for over 13 years where she held roles of increasing responsibility and was the Global Vice President of Drug Product Development where she oversaw teams in the US and Japan responsible for drug product development and manufacturing, device and combination product development, and product innovation.  While at Takeda, Willow advanced numerous clinical development candidates and was instrumental in the development and approval of monoclonal antibody products Entyvio® IV and Entyvio® SC and oral oncology product Ninlaro® and Willow also worked at DuPont Pharmaceuticals.

Willow holds a Ph.D. in Engineering from Harvard University and a Bachelor of Science in Chemical Engineering from The University of Massachusetts at Amherst.

Senior Vice President, Legal and Human Resources

Ben is an experienced and strategic leader with a proven track record of helping companies scale and innovate. As Senior Vice President, Ben leads Elektrofi’s legal and HR functions with a focus on protecting innovation, supporting business growth, mitigating risks, and ensuring compliance in a rapidly evolving landscape.

With a deep expertise in intellectual property and corporate law, Ben has been instrumental in helping companies build, manage, and enforce patent portfolios, and license patents and other technology. Ben has also helped numerous startup companies build and enhance the legal infrastructure necessary to support growth, and negotiate transformative agreements, whether by license, partnership, or M&A.

Ben has over two decades of experience working with companies at all stages of development. Prior to joining Elektrofi, Ben served as VP, Legal Affairs at Theseus Pharmaceuticals, General Counsel at Tremeau Pharmaceuticals, General Counsel at Finch Therapeutics, and Corporate Counsel at Moderna and Sunovion Pharmaceuticals. Ben began his career as a litigation associate at two national law firms, Holland & Knight and Fish & Richardson.

Ben holds a J.D. from Cornell Law School (cum laude) and a Bachelor of Arts in Chemistry and Anthropology from Vanderbilt University.

Angela Hui

Vice President, Operations

Angela Hui leads the company’s lab operations and facilities teams, responsible for laboratory operations and facilities management to ensure the efficient and effective functioning of our scientific research and development efforts. She also oversees the company’s information technology systems. 

She is an accomplished operations leader with proven experience designing lab spaces and management. Angela has significant expertise within the areas of lab operations oversight, facility design, and sample management. Prior to joining Elektrofi, Angela led a site team for SmartLabs and held roles of increasing responsibilities for 15 years at Amgen in R&D Lab operations. During this time, she supported its Discovery Research business focused on process optimization, cross-site alignment, and operational excellence. 

Angela has a Bachelor of Science from Northeastern University. She is a board member of LabOps Unite Community, a global community of operations professionals, where she serves as vice chair and leads its mentorship program across the United States, Europe, and Canada.

Senior Vice President, Technical Operations

Jason Martin is Elektrofi's SVP, Head of Technical Operations responsible for Internal & External Manufacturing, Supply Chain, MS&T, Corporate Operations, Laboratory Operations, Facilities & Engineering, Environment Health & Safety, Security, and Information Security & Technology.

Jason is highly accomplished with over twenty-five years of progressive business and operations experience in the domestic and global biopharmaceutical industry.  He is an enterprise leader with proven track record of executing successful strategic initiatives, startups, turnarounds, product launches, and oversight of manufacturing operations from early clinical phase through routine commercial supply.  His passion is leveraging novel technologies to manufacture products that improve patients' health worldwide.

Prior to Elektrofi, Jason held various roles at Bristol Myers Squibb in the cell therapy division as VP Cell Therapy Operations Global Manufacturing Science & Technology, Global Head of Cell Therapy Network Strategy & Planning, and Site Head of Cell Therapy Manufacturing.  While at BMS, he worked on Abecma® and Breyanzi® commercialization and four INDs for novel cell therapy clinical pipeline products.

Jason also held roles at Novartis as Americas Head of External Supply Operations Business Development & Product Launch and Director of Americas External Supply Quality Operations.  While at Novartis, he worked on the commercial launch of 40 products including the first US FDA Approved Biosimilar Zarxio™ (filgrastim-sndz) and Glatopa®.  He had quality oversight of 54 commercial products including Enoxaparin, Decitabine, Budesonide, & Cyclophosphamide manufactured at CDMOs globally and supplied to the Americas region.

Early in his career, Jason worked at Merck & Co., Inc. in various Technical Operations roles in both the small molecule and vaccine divisions.  While at Merck, he supported the manufacturing of 40 sterile biological vaccines and pharmaceutical drug products. He worked extensively on development and commercialization of Gardasil®, RECOMBIVAX®, HEXAVAC® (via JV with Sanofi), and INVANZ®.

Jason has a M.ENG. Chemical Engineering (minor biotechnology) and B.S. Chemical Engineering (pre-medical) degrees from Lehigh University.

Senior Director, Process Development

Chaitanya Sudrik leads Elektrofi's Process Development team and is responsible for the ongoing development and scale-up of the company’s platform manufacturing process. Prior to leading this team, Chaitanya was responsible for developing platform formulation approaches that enable subcutaneous delivery of ultra-high concentration biologics.

Chaitanya is a respected thought leader, having authored and spoken at conferences on topics including protein stability, pre-formulation, and thermodynamics of protein-excipient interactions. He has authored several peer-reviewed articles on the topics of excipient-mediated protein stabilization, riboswitches, and optogenetics. 

Prior to joining Elektrofi, Chaitanya conducted his post-doctoral training at the Molecular Engineering Laboratory at Massachusetts Institute of Technology where he conducted research on the development of high concentration protein formulations. 

Chaitanya holds a Ph.D. in Chemical and Biological Engineering from Rensselaer Polytechnic Institute and a Bachelor of Science in Chemical Engineering from the Institute of Chemical Technology, Mumbai.

Vice President, Quality Assurance

With over 25 years of global experience in the life sciences, Rozanna brings depth and breadth in Quality, technical, and strategic expertise in drug and device product development and manufacturing from clinical to product launch and commercialization.  She leverages scientific and regulatory knowledge, and industry best practices to solve complex product development, technical operations, and quality challenges, enabling fruitful execution and navigating the regulatory landscape more expeditiously.  She came to Elektrofi from Finch as the Head of Quality overseeing QC, QA, QS, and CQA where she grew a team of five to 25+ in support of clinical operations and GMP activities, built a QMS for Phase 3 and beyond, expanded GMP QC internal capabilities, developed the commercial manufacturing site validation master plan for microbiome production, and supported Finch IPO. She prepared and hosted numerous regulatory inspections including for-caused, routine, and pre-approval inspections (PAI) at companies like AxoGen, uniQure, Genzyme, Shire HGT, and Boston Scientific. She started her career as a chemist at AstraZeneca and moved on to other life sciences companies serving in key leadership, quality, and consulting roles at Stryker, Boston Scientific, Applied Biosystems (Thermo Fisher), Genzyme (Sanofi), Shire HGT (Takeda), Stemline Therapeutics, Axogen, uniQure, and numerous other startups.

Rozanna holds a BS in Chemistry from Boston College, MBA from MIT Sloan School of Management, and a Venture Capital and Private Equity Business Certificate from Columbia Business School.

Executive Director, Analytical Development

Bernice Yeung leads the Analytical Development group at Elektrofi. In this role, she is accountable for delivering innovative and robust analytical methods to support the process development of HyperconTM formulations, that are fit-for-purpose and stage-appropriate. The group performs product characterization using state-of-the-art analytical techniques to assess the biochemical and biophysical properties of microparticle suspension drug products to ensure quality and stability. She is also accountable for the external technical transfer that enables the manufacturing of these drug product presentations as well as the definition of their analytical control strategy.

Prior to joining Elektrofi, Bernice worked at several major biopharmaceutical companies, including Amgen, Bristol-Myer Squibb, Shire and Biogen, mostly in analytical CMC and biologics process development. She also held a post-doctoral fellowship at Genetics Institute, Inc. (now Pfizer).

Bernice holds a Ph.D. in Analytical Chemistry from Northeastern University and a B.S. in Chemistry from the University of Delaware.